Step 1 topics → Psychiatry → Carbamazepine and Lamotrigine (Mood Stabilizers)

Carbamazepine and Lamotrigine (Mood Stabilizers)

USMLE Step 1 trap: Confuses carbamazepine as a CYP inducer with a CYP inhibitor. Carbamazepine is a potent CYP450 inducer (including its own metabolism — autoinduction), which lowers levels of many drugs including oral contraceptives, warfarin, and other anticonvulsants.

Carbamazepine and lamotrigine are second-line mood stabilizers used in bipolar disorder when lithium fails or isn't tolerated. USMLE Step 1 tests these drugs through two lenses: mechanism-plus-toxicity for carbamazepine, and clinical niche-plus-safety-caveat for lamotrigine. Neither drug is complicated in isolation — the tricky part is that students conflate their toxicity profiles, misremember carbamazepine's CYP relationship, and miss the titration-dependency of lamotrigine's most dangerous side effect.

Carbamazepine is a sodium channel blocker (same as phenytoin) that also carries a dense toxicity profile: SIADH causing hyponatremia, aplastic anemia, agranulocytosis, and SJS/TEN. It's also a potent CYP450 inducer — including autoinduction of its own metabolism. This last point is a classic Step 1 trap: students who haven't locked in the inducer/inhibitor distinction will say carbamazepine inhibits CYP450, which is backwards. The clinical consequence is real: it lowers levels of oral contraceptives, warfarin, and other anticonvulsants.

Lamotrigine's entire exam story revolves around two facts: it works for bipolar depression (not mania), and SJS risk is not fixed — it spikes with rapid titration or co-administration with valproate, which blocks lamotrigine's glucuronidation and drives plasma levels up. USMLE Step 1 will hand you a vignette where a patient on valproate is started on lamotrigine too fast and develops a rash, expecting you to know exactly why the risk is elevated. Slow titration isn't a footnote — it's the central safety concept for this drug.

From real student decks
46%have cards covering this topic
32%have mature cards

Common misconceptions

Common mistake
Wrong: Carbamazepine's drug interactions are due to inhibition of CYP450 enzymes.
Right: Carbamazepine is a potent CYP450 inducer (including its own metabolism — autoinduction), which lowers levels of many drugs including oral contraceptives, warfarin, and other anticonvulsants.
Carbamazepine is one of the classic CYP450 inducers on Step 1 — it upregulates hepatic enzymes, increasing drug metabolism across the board. This means it lowers plasma levels of co-administered drugs like warfarin, oral contraceptives, and other anticonvulsants. The 'autoinduction' twist means it even accelerates its own metabolism over time, so early doses achieve higher levels than later doses at the same dose — a fact that sometimes appears in kinetics-flavored questions. Never confuse this with CYP inhibitors like valproate or fluoxetine, which raise drug levels by slowing metabolism.
Common mistake
Gap: Missing knowledge of carbamazepine's distinctive toxicities including SIADH and aplastic anemia
Carbamazepine causes SIADH (hyponatremia), aplastic anemia, agranulocytosis, and Stevens-Johnson syndrome, and requires CBC and sodium monitoring.
Carbamazepine has one of the densest toxicity profiles of any anticonvulsant-mood stabilizer. The two most distinctive and high-yield toxicities are SIADH (causing hyponatremia — relevant especially in elderly patients) and aplastic anemia/agranulocytosis (a rare but life-threatening bone marrow effect). SJS/TEN rounds out the serious end of the spectrum. Because of the hematologic risks, baseline and periodic CBC monitoring is required, and sodium levels should be tracked given the SIADH risk. If a vignette shows an elderly bipolar patient on carbamazepine with confusion and low sodium, SIADH is the answer.
Common mistake
Wrong: Lamotrigine's SJS risk is fixed and unrelated to dosing speed.
Right: Lamotrigine's risk of Stevens-Johnson syndrome is dramatically increased by rapid dose titration or co-administration with valproate (which inhibits lamotrigine glucuronidation), so slow titration is mandatory.
Lamotrigine does carry baseline SJS risk, but the risk is strongly modifiable by how you use the drug — it is not a fixed probability. Two factors dramatically increase risk: titrating the dose too quickly, and adding valproate to the regimen. Valproate inhibits UDP-glucuronosyltransferase, the enzyme responsible for lamotrigine glucuronidation, which causes lamotrigine levels to roughly double. High lamotrigine levels drive SJS risk up steeply. The clinical rule is: if a patient is on valproate, start lamotrigine at half the usual dose and titrate even more slowly. Exam questions will test whether you know the mechanism of the interaction, not just that the interaction exists.
Common mistake
Gap: Missing knowledge that lamotrigine's niche is bipolar depression maintenance, not acute mania
Lamotrigine is uniquely effective for the depressive phase of bipolar disorder and is a first-line maintenance agent, but has minimal efficacy for acute mania.
Lamotrigine occupies a specific and narrow niche in bipolar pharmacology: it is effective for preventing depressive episodes and is a first-line maintenance agent for bipolar disorder, particularly when depression is the dominant pole. It does not work for acute mania — this is a high-yield distinction because students assume that a 'mood stabilizer' must cover both poles equally. If a vignette asks what to add for a bipolar patient whose main burden is recurrent depression (not mania), lamotrigine is the answer. If the patient is in acute mania right now, lamotrigine is not your drug.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know carbamazepine's mechanism (sodium channel blockade) and its full toxicity profile: SIADH/hyponatremia, aplastic anemia, agranulocytosis, and SJS/TEN — and what monitoring is required (CBC, sodium levels).
  2. Understand that carbamazepine is a potent CYP450 inducer — not inhibitor — and that this includes autoinduction of its own metabolism, reducing levels of oral contraceptives, warfarin, and other anticonvulsants.
  3. Know lamotrigine's clinical niche: first-line maintenance therapy for the depressive phase of bipolar disorder, with minimal efficacy against acute mania.
  4. Understand why lamotrigine's SJS/TEN risk is not fixed: rapid dose titration increases risk, and co-administration with valproate (which inhibits lamotrigine glucuronidation) dramatically elevates plasma lamotrigine levels and SJS risk — making slow titration mandatory.

Can you avoid these mistakes?

A 32-year-old woman with bipolar disorder is started on carbamazepine. Two months later her warfarin INR is subtherapeutic despite compliance. What is the mechanism, and what other drug class is classically affected by this same interaction?
A 45-year-old man on carbamazepine for bipolar disorder presents with confusion and serum sodium of 126 mEq/L. His urine osmolality is elevated. What toxicity is this, and what other hematologic toxicities require monitoring on this drug?
A patient with bipolar disorder on valproate is started on lamotrigine with standard titration. Two weeks later she develops a spreading erythematous rash with mucosal involvement. What is the mechanism by which valproate increased her lamotrigine toxicity risk?
A psychiatrist is choosing between lithium and lamotrigine for a bipolar I patient whose main problem is frequent depressive episodes with rare hypomanic episodes. Which drug is better suited and why? What would your answer be if the patient were in acute mania right now?

Related topics

Bipolar I Disorder Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →